New Jersey’s VaxInnate is developing inoculations to ward off seasonal and pandemic flu, dengue fever and Clostridium difficile. The well-capitalized company has raised a recent round of $6 million, according to a regulatory filing.
The company genetically fuses vaccine antigens to flagellin, a protein that forms the flagella of a bacterium that’s known for being highly recognizable by the immune system. Indeed, mammals in particular are known to have a strong innate (thus the company’s name) immune response to flagellated bacteria.
Help employers find you! Check out all the jobs and post your resume.
The company genetically fuses vaccine antigens to flagellin, a protein that forms the flagella of a bacterium that’s known for being highly recognizable by the immune system. Indeed, mammals in particular are known to have a strong innate (thus the company’s name) immune response to flagellated bacteria.
Help employers find you! Check out all the jobs and post your resume.
